2024 International Congress Archives - Page 90 of 181

Improvement in Upright Stability subscale of mFARS with Vatiquinone Treatment in MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)
Improving awareness of motor fluctuations in Parkinson’s Disease: an educational patient support program using a waist-worn device.

N. Caballol, A. ávila, A. Planas-Ballvé, A. Peral, J. Hernández-Vara, S. Belmonte, S. Enríquez, S. Sánchez, D. Cerdán, I. Cabo, N. López-Ariztegui, G. Carvalho, JM. Velázquez, T. Delgado, J. Bocos, B. Ruiz, B. Claramonte, J. Herreros-Rodríguez, D. Santos-García, C. Cores-Bartolomé, J. González-Ardura, D. Ceberino, JM. Salom, R. Rashid, A. Méndez, C. Madrid-Navarro, A. Mulet, D. Rodríguez-Martín, I. Pijuan, I. Tegel (Sant Joan Despí, Spain)
Improving Neuropsychiatric Comorbidity in Geriatric Spinocerebellar Ataxia

M. Le, B. Carr (Gainesville, USA)
Improving Work Up amongst Patients with Rare Movement Disorders according to Diagnostic Yield Findings– Update from Single Center Neurogenetic Clinic

D. Penn, Y. Amir, G. Ben David, J. Zitser Koren, G. Gurevich, H. Baris Feldman, R. Alcalay, Y. Yaron, P. Ponger (Tel Aviv, Israel)
In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease

C. Mahapatra (Mumbai, India)
Incidence and Prevalence of Parkinson’s Disease Among United States Medicare Beneficiaries by Age, Sex, Race/Ethnicity, and Neighborhood Socioeconomic Status 2014-2021

T. Rosa, S. Mantri, C. Ford, S. Soneji, B. Kaufman, F. Li, B. Grory, Y. Xian, K. Johnson, R. O’Brien, E. O’Brien, J. Lusk, B. Hammill (Durham, USA)
Incidence of Depression in the Caregivers of Parkinson’s Disease Patients

S. Soleimani, M. Salari, F. Hojjati Pour (Tehran, Islamic Republic of Iran)
Incident & Prevalent Dementia in Individuals with Parkinson’s Disease in the Framingham Heart Study

J. Dookhy, Y. Li, A. Gurnani, S. O'Shea, S. Frank, R. Au, J. Mez, Y. Liu, TFA. Ang, L. Shih (Galway, Ireland)
Inclusion of PSP-Parkinsonism (PSP-P) phenotype in clinical trials – power calculation

N. Olfati, S. Akhlaghi, A. Shoeibi, I. Litvan (San Diego, USA)
Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)